HEALTHCARE & PHARMACEUTICALS MARKET RESEARCH
Category: Haemophilia
-
$5000 million Market: Haemophilia Gene Therapy
A bleeding ailment called haemophilia slows down blood clotting process. This syndrome causes prolonged bleeding or oozing to occur after an injury, surgery, or tooth extraction in affected individuals.
-
Roctavian – A captivating Haemophilia therapy; 5 advantages and disadvantages
Roctavian, a gene therapy product developed by BioMarin, has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hemophilia A(It is a form of bleeding)
Follow Us
Recent Posts
-
Bedaquiline Role in Treating Tuberculosis having a hefty $1.38 billion dollar market
-
Adalimumab’s competition and immense market Growth Potential of 5.1%
-
Semaglutide’s massive influence on the Diabetes Pharmaceutical Market and 6 competitors
-
FDA approved Leqembi to have $12.9 billion sales
-
Assistive Technology Market; a $82B Growth Story
Tags
Autoimmunity cancer cancer research cancer therapy CDSCO covid-19 covid in children Diabetes drug Elderly Health FDA healthcare immune response Kerala mutations Nipah virus pandemic PCOS pharma Pharmaceutical market pharma sector protein-based vaccines sars-cov-2 therapy third wave Treatment vaccine variants WHO zydus cadila